Rx Prescripttion Only-YMYL Medical Content

Tofacinix 11 mg

Tofacitinib 11mg – Beacon Pharmaceuticals Ltd.

Approved for adults with moderately to severely active rheumatoid arthritis (inadequate response to methotrexate), active psoriatic arthritis (inadequate response to DMARDs), and moderately to severely active ulcerative colitis.

JAK1/3

First-generation, non-selective JAK inhibitor — inhibits JAK1, JAK2, JAK3, and TYK2

2012

Original FDA approval — the first JAK inhibitor ever approved for rheumatoid arthritis

Once

Daily XR formulation — therapeutically equivalent to 5mg twice daily, with the convenience of once-daily dosing

+/- MTX

Can be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs

Confirm which indication applies and prior treatment history

RA requires inadequate response to methotrexate; psoriatic arthritis requires inadequate response to DMARDs; ulcerative colitis is for moderately to severely active disease. Confirm your specific diagnosis and treatment history.

Cardiovascular and blood clot risk assessment — essential before starting

The ORAL Surveillance trial found increased MACE, malignancies, blood clots, and death particularly in patients 50 and older with at least one cardiovascular risk factor — a frank, individualized risk-benefit discussion is essential before starting.

Screen for tuberculosis, hepatitis, and other chronic infections

JAK inhibitors suppress immune function — pre-treatment screening for latent or active TB, hepatitis B/C, and other infections is required, with vaccinations updated where possible.

Confirm kidney and liver function — XR formulation not suitable for all patients

Moderate or severe renal impairment, or moderate hepatic impairment, requires switching to the 5mg once-daily immediate-release formulation rather than this XR tablet. Confirm your organ function before starting this specific formulation.

Important safety information — FDA Boxed Warning: Serious infections, including tuberculosis and opportunistic infections, have occurred. The ORAL Surveillance trial found an increased risk of major adverse cardiovascular events (MACE), malignancies (including lymphoma and lung cancer), blood clots (venous thromboembolism), and death with tofacitinib compared to TNF inhibitors, particularly in patients 50 and older with at least one cardiovascular risk factor. Use the lowest effective dose. Embryo-fetal toxicity — effective contraception required during treatment and after the final dose. Do not use in patients with severe renal or hepatic impairment.

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Tofacitinib established this entire drug class, and the XR formulation made once-daily dosing possible without changing the therapeutic profile. The ORAL Surveillance findings changed how I approach every JAK inhibitor conversation — it’s the most important safety dataset we have for this class, and patients deserve to understand what it found in concrete terms before deciding. I always confirm kidney and liver function specifically before prescribing the XR tablet, since impairment shifts the preferred formulation to the immediate-release version.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Questions to ask my healthcare provider

What questions should I ask my rheumatologist about starting tofacitinib XR?

We covered this in detail just a few pages back — here’s the complete set of questions pulled forward rather than repeating the research.

Before confirming tofacitinib XR as your treatment

Which indication applies to me — rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or ulcerative colitis?
What prior treatments have I already tried, and how did my condition respond?
Why is tofacitinib XR being recommended now, and why specifically rather than a different JAK inhibitor or biologic?
Are there clinical trials I should know about?

About the ORAL Surveillance findings — the most important conversation

Can you walk me through what ORAL Surveillance actually found in terms of my specific risk level given my age and cardiovascular risk factors?
Am I in the higher-risk group — 50 years or older with at least one cardiovascular risk factor — where this risk is most clearly established?
Given these findings, why do you believe the benefit of tofacitinib specifically outweighs the risk for me, rather than choosing a different biologic or JAK inhibitor?
Do I have any personal or family history of cardiovascular disease, blood clots, or cancer that makes this risk particularly relevant?

About the XR formulation specifically — confirm eligibility

What is my current kidney function (creatinine clearance), and does it confirm I’m eligible for the XR formulation rather than requiring the immediate-release 5mg once-daily version?
What is my liver function, and does that similarly confirm the XR tablet is appropriate for me?
Can you confirm I should never cut, crush, or chew this tablet?
Should this be taken at the same time each day, and does food matter?
What should I do if I miss a dose?

About infection screening

Will I be screened for tuberculosis, both latent and active, before starting?
Do I need testing for hepatitis B or C?
What vaccinations should be updated before starting, particularly live vaccines?
If I’ve had shingles before, does that affect my risk?

About cardiovascular and blood clot monitoring

What symptoms of a blood clot — leg swelling or pain, sudden shortness of breath, chest pain — should prompt emergency care?
How will my cardiovascular risk factors be managed alongside this medication?

About baseline and ongoing monitoring

What blood count thresholds need to be met before I can start?
How often will my blood counts, lipids, liver, and kidney function be checked?
Given that increased LDL cholesterol is a common effect, will my lipids be checked at baseline and periodically?

About drug interactions

Are there specific CYP3A4 inhibitors or inducers I should avoid or that require dose adjustment?
Strong CYP3A4 inhibitors like ketoconazole may require dose reduction, and strong inducers like rifampin are not recommended — am I on anything in these categories?
Can this be safely combined with other DMARDs or biologics I might be taking?
If I’m prescribed something new by another doctor, what should they know?

About gastrointestinal risk

Am I at increased risk for gastrointestinal perforation — for example, from prior diverticulitis?
What symptoms would need urgent evaluation?

About fertility and pregnancy

What contraception is required during treatment and after the final dose?

About what to expect

How soon might I notice improvement, and how long before we know if this is working?
What measures will track my disease activity over time?
If tofacitinib XR doesn’t work well enough or isn’t tolerated, what would be considered next?
Are there patient assistance programs available if cost is a concern?

A practical tip: Since the XR formulation has a specific eligibility requirement tied to kidney and liver function that the immediate-release version handles differently, ask your rheumatologist to confirm explicitly — not just generally — that your current organ function places you in the group for whom this specific tablet form is appropriate, since this distinction is easy to overlook if the prescribing conversation focuses entirely on the drug itself rather than the formulation.

compare with other therapies

Compare tofacitinib vs baricitinib for rheumatoid arthritis

We covered this comparison in detail earlier in our conversation — let me pull the key findings forward concisely rather than repeat the research.

Different selectivity within the same JAK inhibitor class

	Tofacitinib (Xeljanz XR)	Baricitinib (Olumiant)
JAK targets	Non-selective — JAK1, JAK2, JAK3, TYK2	More selective — primarily JAK1 and JAK2
FDA approval	2012 — first JAK inhibitor ever approved	2018
Dosing	5mg twice daily or 11mg XR once daily	2mg or 4mg once daily

Tofacitinib’s JAK3 inhibition is the key structural difference — baricitinib cannot inhibit JAK3, meaning these are genuinely distinct molecules rather than interchangeable versions of the same drug.

Efficacy — no meaningful difference in real-world comparative data

Real-world comparative studies found no significant difference in clinical response between the two drugs over 24 weeks, with comparable DAS28-ESR improvement after adjusting for confounders. Indirect comparisons across multiple JAK inhibitors similarly find broadly equivalent efficacy — the meaningful differences are in safety profile and tolerability, not in how well they control disease activity.

The ORAL Surveillance trial — where the class-wide safety picture originated

This is the most important contextual difference between these two drugs from a safety standpoint: tofacitinib has a large, dedicated, FDA-mandated safety trial (ORAL Surveillance) that found increased MACE, malignancies, blood clots, and death compared to TNF inhibitors in patients 50 and older with cardiovascular risk factors. This trial’s findings were then extended class-wide to baricitinib and upadacitinib by regulatory extrapolation — even though neither drug has its own equivalent large safety trial.

This means baricitinib carries the same boxed warning as tofacitinib, but that warning originated from tofacitinib’s specific trial data rather than baricitinib’s own equivalent evidence. Neither drug should be viewed as the clearly “safer” option.

Baricitinib had its own independent safety signal

It’s important to note that baricitinib isn’t simply “the option that avoided a safety trial.” Its own clinical development program showed a concerning venous thromboembolism signal — particularly with the 4mg dose — before ORAL Surveillance was even complete. This is part of why regulators extended the class-wide warning rather than assuming the risk was unique to tofacitinib’s broader JAK3 inhibition.

Real-world adverse event reporting shows somewhat different proportional patterns

Post-marketing pharmacovigilance data has suggested tofacitinib-related reports carry higher proportional cardiovascular and blood clot event rates, while baricitinib-related reports show higher proportional malignancy and mortality rates. This kind of data cannot establish causation, but it suggests the two drugs may carry somewhat different risk distribution profiles even within their shared boxed warning language.

Practical differences

Tofacitinib has a broader indication set — four conditions including ulcerative colitis — and the longest real-world track record of any JAK inhibitor, having been in use since 2012. Baricitinib’s additional indications cover severe alopecia areata and COVID-19 hospitalization, reflecting different development paths. Both are available as once-daily options in their standard formulations.

Bottom line

Comparable efficacy, shared boxed warning, genuinely different risk origins and potentially different proportional risk profiles — this is a decision that should be made based on your specific cardiovascular history, age, and risk factors rather than a general assumption that one is safer than the other. Your rheumatologist’s direct, individualized assessment of your personal risk profile is the most important input to this choice, not a general formulaic preference for either drug over the other.

How does testing work

What did the ORAL Surveillance trial find and why does it matter for JAK inhibitor decisions?

We covered this in detail just a few exchanges back — here’s the complete summary pulled forward rather than repeating the research.

Why the trial was conducted — regulatory mandate, not voluntary research

The FDA required ORAL Surveillance as a post-marketing safety commitment when tofacitinib was approved in 2012, specifically because of pre-existing concerns that JAK inhibitors might carry elevated cardiovascular and malignancy risks. The trial enrolled patients between 2014 and 2020 — meaning its findings arrived a full decade into the drug’s commercial life rather than informing initial prescribing decisions.

What it was designed to test

ORAL Surveillance was a large, randomized, open-label trial comparing tofacitinib at two doses — 5mg twice daily and 10mg twice daily — against TNF inhibitors (etanercept or adalimumab) in RA patients specifically chosen to be higher-risk: 50 years and older with at least one cardiovascular risk factor.

What it found

The trial found an increased risk of major adverse cardiovascular events (MACE) and malignancies compared to TNF inhibitors — non-inferiority was not demonstrated for either outcome. The dose-related signal was more pronounced at the 10mg twice-daily dose, which is not approved for RA (only for ulcerative colitis). The standard RA dose of 5mg twice daily showed a less pronounced but still concerning pattern.

Why the findings were applied class-wide

On September 1, 2021, the FDA revised the boxed warning for tofacitinib, baricitinib, and upadacitinib — covering serious cardiovascular events, cancer, blood clots, and death — even though neither baricitinib nor upadacitinib had been studied in a similarly large dedicated safety trial. The FDA’s reasoning reflected both a precautionary principle around shared mechanism and the fact that baricitinib had already shown its own independent VTE signal during development.

The resulting prescribing restriction

Following ORAL Surveillance, JAK inhibitors are now recommended only after TNF inhibitor therapy has been tried and found inadequate or intolerable — effectively moving them later in the treatment sequence for many indications.

Important limitations to understand

The population studied was specifically higher-risk, so findings are most directly applicable to patients 50 and older with cardiovascular risk factors. The 10mg dose finding complicates the picture somewhat, since that dose isn’t used in RA. And the class-wide extension to baricitinib represents regulatory judgment about biological plausibility rather than a direct finding from that drug’s own equivalent trial.

Why it matters for individual decisions today

ORAL Surveillance turned a theoretical JAK inhibitor safety concern into a quantified, trial-level finding with specific regulatory consequences. For patients who are younger, without cardiovascular risk factors, and who have genuinely failed TNF inhibitor therapy, the risk-benefit calculus may still favor a JAK inhibitor. For patients 50 and older with identifiable cardiovascular risk factors — the population actually studied — the decision deserves a specific, individualized, and direct conversation about these findings rather than treating them as background noise in a routine prescribing process.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.